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Abstract
Background: Nitric oxide (NO), an important signaling molecule with biological functions, has antimicrobial activity
against a variety of pathogens including viruses. To our knowledge, little information is available about the regulatory
effect of NO on porcine circovirus type 2 (PCV2) infection. This study was conducted to investigate the antiviral activity
of NO generated from S-nitrosoglutathione (GSNO), during PCV2 infection of PK-15 cells and BALB/c mice.
Results: GSNO released considerable NO in the culture medium of PK-15 cells, and NO was scavenged by its
scavenger hemoglobin (Hb) in a dose-dependent manner. NO strongly inhibited PCV2 replication in PK-15 cells, and
the antiviral effect was reversed by Hb. An in vivo assay indicated that GSNO treatment reduced the progression of
PCV2 infection in mice, evident as reductions in the percentages of PCV2-positive sera and tissue samples and in the
viral DNA copies in serum samples. GSNO also improved the growth performance and immune organs (spleens and
thymuses) of the PCV2-infected mice to some degree.
Conclusions: Our data demonstrate that the NO-generating compound GSNO suppresses PCV2 infection in PK-15 cells
and BALB/c mice, indicating that NO and its donor, GSNO, have potential value as antiviral drugs against PCV2 infection.
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Background
Porcine circovirus type 2 (PCV2), which belongs to the
family Circoviridae, is a small, non-enveloped virus with
a circular, single-stranded DNA genome [1]. PCV2 is the
primary causative agent of porcine circovirus-associated
disease (PCVAD) [2], a globally emerging disease, cur-
rently causing great economic losses in the global swine
industry today [3]. The most significant pathological
conditions considered to be PCVADs are post-weaning
multisystemic wasting syndrome, porcine dermatitis and
nephropathy syndrome, and PCV2-reproductive disease
[4, 5]. PCV2-infected piglets are readily contract con-
comitant infections, including porcine respiratory and
reproductive syndrome virus, porcine parvovirus and
Haemophilus parasuis, suggesting that PCVAD is
actually an immunosuppressive disease [6]. Besides pig-
lets, mice and calves are also found to be able to infect
this virus [7, 8]. The control of PCVD is based on manage-
ment strategies, control of coinfections, and vaccination
[9]. Vaccination is traditionally considered the most effect-
ive method for preventing viral diseases, but the period of
protection afforded by a vaccine is limited and the virus
cannot be eradicated by vaccination [10]. Furthermore, no
effective vaccines are available for preventing multifactorial
diseases such as PCVAD [11]. Therefore, alternative effect-
ive measures to control the disease are urgently required.
NO is an important molecule with key roles in a broad
range of biological processes including neurotransmission,
vasodilatation and immune responses [12]. NO is gener-
ated by mammalian cells from the guanidino nitrogen of
L-arginine in a reaction catalyzed by a family of NO
synthase enzymes [13]. NO can also be released from
exogenous donors, such as sodium nitroprusside (SNP),
S-nitroso-acetylpenicillamine (SNAP) and GSNO [14].
Previous studies have presented considerable evidence
that NO can prevent viral infections [15–20]. However,
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the antiviral effects of NO against PCV2 infection are
so far poorly studied.
In this study, the NO-generating compound GSNO
was used to analyze the kinetics of NO production in
the culture supernatant of PK-15 cells. The antiviral ac-
tivity mediated by GSNO during PCV2 infection was
also investigated in PK-15 cells and BALB/c mice.
Methods
Cells and virus
PCV-free PK-15 cells, purchased from the China Institute
of Veterinary Drug Control (Beijing, China), were grown at
37 °C in an atmosphere of 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma, USA) supplemented with
10% fetal bovine serum (GIBCO, USA) and 1% penicillin-
streptomycin antibiotics (Sangon, China). The PCV2-
Haian strain (GenBank accession number: FJ712216.1) is
maintained by Institute of Veterinary Medicine, Jiangsu
Academy Agricultural Sciences, Jiangsu, China. PCV2 was
propagated in PK-15 cells, harvested after incubation for
72 h, and stored at −70 °C until use.
Experimental design
In vitro
The safe concentrations of the drugs were determined in
PK-15 cells with a 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay, and the kinet-
ics of NO production in the culture supernatant were
assessed from 0 to 96 h after drug treatment. To investi-
gate the antiviral activity of the NO-generating com-
pound GSNO during PCV2 infection in vitro, 80%
confluent PK-15 cells in 24-well cell culture plates were
pretreated with GSNO or GSNO plus hemoglobin (Hb)
for 6 h, and then infected with PCV2 (multiplicity of in-
fection (MOI) of 1) in the presence of the drugs for an
additional 72 h. Untreated cells, cultured in medium
alone, were used as the mock control, and cells infected
with PCV2 alone (MOI = 1) were used as the PCV2-
infected control. The antiviral activity of GSNO was de-
termined from the appearance of PCV2-infected cells,
viral titers, and PCV2 DNA copy numbers. The NO
levels in the various groups were also determined.
In vivo
Seventy-eight 4-week-old specific-pathogen-free BALB/c
mice were purchased from the Comparative Medicine
Centre, Yangzhou University, Jiangsu, China. The mice were
maintained in isolation rooms, in which the temperature
was maintained at 25 °C under a 12-h light cycle. The ex-
perimental animals were allowed to acclimatize for 7 days.
The protocols for the care and use of animals in this study
were approved by the Committee on the Ethics of Animal
Experiments of Jiangsu Academy of Agricultural Sciences.
The mice were randomly divided into three groups, each
containing 26 animals. The mice in group I were injected in-
traperitoneally with 0.2 ml of phosphate-buffered saline
(PBS) and intranasally with 0.02 ml of PBS, and used as
negative control(NC). Mice in group II were inoculated
intraperitoneally with 0.2 ml of PCV2 (105 TCID50/ml)
and intranasally with 0.02 ml of PCV2 (105 TCID50/ml),
and used as the PCV2-infected control. The mice in group
III were inoculated intraperitoneally with 0.2 ml of PCV2
(105 TCID50/ml) and intranasally with 0.02 ml of PCV2
(105 TCID50/ml), and injected intraperitoneally with
0.1 ml of GSNO (10 mM) once daily from 0 to 6 days
postinoculation (DPI). To exclude the stress induced by
the injection, the mice in groups I and II were also
injected intraperitoneally with 0.1 ml of PBS once daily
at 0–6 DPI. At -1, 12, 17, 22, 27, and 32 DPI, all the
mice were weighed, and necropsies were performed on
four mice from each group. At 6 DPI, blood samples
were withdrawn from the orbital venous plexus of each
mouse to isolate serum for the detection of NO. At the
time of necropsy, serum samples and tissue samples
were collected and stored at −70 °C for PCV2 polymer-
ase chain reaction (PCR) or real-time PCR. The spleen
and thymus from each killed mouse were weighed to
calculate the organ indexes. The mice were monitored
daily and evaluated for clinical signs throughout the
trial.
Cytotoxicity assay
In this study, we used GSNO (Sigma, USA) as the exogen-
ous NO donor; Hb (Sigma, USA), as the NO scavenger to
scavenge the NO released from GSNO. The cytotoxicity
of the drugs was evaluated with a MTTassay. In brief, PK-
15 cells were seeded in 96-well cell culture plates at a
density of 5 × 104 cells/well. When the cells in each well
reached 80% confluence, they were washed twice with
PBS and treated with different concentrations of the drugs
as serial two-fold dilutions, with eight wells for each
concentration. After incubation for 72 h, the viability of
PK-15 cells was evaluated with a colorimetric MTT
assay, as reported previously [11]. The absorbance at
570 nm (A570) of each well was measured with a micro-
liter enzyme-linked immunosorbent assay reader (Sunrise,
TECAN Co., Switzerland).
Measurement of NO
NO production was measured with a colorimetric assay
using the Griess reaction [21]. Briefly, at various time
points during cell culture, the supernatants (100 μl/well)
were harvested, and incubated with an equal volume of
Griess solution (1% sulfanilamide, and 0.1% naphthyl
ethylene diamine dihydrochloride in 5% phosphoric acid)
(Sigma, USA) for 10 min at room temperature. The ab-
sorbance was read at 540 nm, and the concentrations of
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NO were determined from a least squares linear regres-
sion analysis of a standard curve for sodium nitrite.
Indirect fluorescence assay (IFA)
PCV2-based IFA was performed according to previously
described procedures [22]. In brief, cells were fixed in
frozen methanol at 4 °C for 10–15 min. The fixed cells
were washed with PBS, and incubated with porcine anti-
PCV2 antibody (VMRD, USA) at 37 °C for 1 h. The cells
were washed with PBS again, incubated with FITC-
conjugated goat anti-pig antibody (Abcam, UK) at 37 °C
for 45 min, washed again with PBS, and examined under
a fluorescence microscope (Olympus, Japan). The cells
positive for PCV2 viral antigens were counted in six
fields of view.
Viral titers
Samples collected from the cell culture plates were frozen
and thawed three times, then serially diluted 10-fold in
DMEM (1:10 to 1:106). PK-15 cells were seeded in 96-well
plates, and when the cells in each well reached 40%–50%
confluence, they were inoculated with the diluted samples,
with eight wells used for each dilution. After incubation
for 48 h, the PCV2-positive samples were detected by IFA,
as mentioned above, and the viral titers were calculated by
Reed-Muench method [23].
DNA extraction, PCR and TaqMan-based real-time PCR
DNA was extracted by using the Column Viral DNAout
Kit (TIANDZ, Beijing, China), according to the manufac-
turer’s instructions. The total DNA was stored at −70 °C
until use.
To evaluate PCV2 viremia or viral loading in the PCV2-
infected tissues of mice, a pair of primers was designed
based on the published sequences of PCV2 (forward
primer 5′-TTACCGGCGCACTTCGGCAG-3′, reverse
primer 5′-ACTCCGTTGTCCCTGAGAT-3′), and PCR
was performed with the thermal cycling parameters:
94 °C for 5 min followed by 30 cycles of 94 °C for
1 min, 58 °C for 1 min, and 72 °C for 1.5 min, with a
final extension step for at 72 °C for 7 min. The PCR
products were subjected to electrophoresis on a 1%
agarose gel.
To analyze the viral DNA copy numbers in the cell
and serum samples, primers and a TaqMan probe specific




TCT[TAMRA]-3′. Taqman-based real-time PCR was
performed on the 7500 Real-Time PCR System (Applied
Biosystems, USA) using the thermal cycling parameters:
95 °C for 30 s, 40 cycles of 95 °C for 5 s and 60 °C for 34 s.
Statistical analysis
The differences among different treatment groups were
analyzed and compared by one-way analysis of variance
(ANOVA), followed by a least-significant difference test,
using the statistical package SPSS ver. 17.0 for Windows.
A value of P < 0.05 was considered statistically significant.
Results
Antiviral activity of GSNO in PK-15 cells
As shown in Fig. 1a, the A570 value of PK-15 cells
treated with 125 μM GSNO did not differ significantly
from that of the control cells in the MTT assay (P > 0.05).
Therefore, 125 μM GSNO was used as a safe
Fig. 1 Cytotoxicity of GSNO and Hb on PK-15 cells tested by MTT
assay. After incubation with the drugs for 72 h, MTT was added into
each well. The cells were cultured for another 4 h, and 200 μl DMSO
was added into each well for dissolving formazan, then A570 of the
samples were determined by a microplate reader. Relative viability
was calculated according to the equation: Relative viability (%) =
A570 of the drug-treated sample / A570 of the untreated sample ×
100. Data shown were means ± SD from three independent experi-
ments. a Cytotoxicity of GSNO on PK-15 cells. b Cytotoxicity of Hb
on PK-15 cells. *P < 0.05, **P < 0.01 vs untreated control group
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concentration for the cells in this study. The safe concen-
tration of Hb for PK-15 cells was determined to be 25 μM
(Fig. 1b).
To determine the kinetics of NO production, the super-
natants of the samples from 24-well cell culture plates was
collected at different time points after drug treatment, and
the NO levels were assayed by the Griess reaction. The
NO production was significantly higher in GSNO-treated
groups, with or without PVC2 infection, than the control
group (P < 0.01; Figs. 2 and 3b). The NO levels tended to
increase in the GSNO-treated groups at 0–72 h after drug
treatment, reaching a plateau at around 72 h (Fig. 2).
However, the NO generated from GSNO was effectively
and dose-dependently scavenged by the NOscavenger Hb
(Fig. 3b).
The inhibitory effect of the NO-generating compound
GSNO on PCV2 replication was shown in Fig. 3. The
PCV2-positive cells detected by IFA indicated that treat-
ment with GSNO reduced the progression of PCV2 in-
fection (Fig. 3a). The percentage of PCV2-infected cells
decreased to 69.5% after treatment with 125 μM GSNO
relative to the infected control (P < 0.05; Fig. 3c), whereas
the percentage of PCV2-infected cells in the groups incu-
bated with 125 μM GSNO plus 5, 10, or 15 μM Hb was
73.3%, 85.5% or 89.7% respectively (Fig. 3c). The viral ti-
ters and viral DNA copy numbers in the PCV2-infected
groups decreased significantly after GSNO treatment rela-
tive to those in the PCV2-infected control (P < 0.01 or P <
0.05; Fig. 3d, e). However, the reductions in the viral titers
and viral DNA copy numbers induced by GSNO were
dose-dependently reversed by the NO scavenger Hb
(Fig. 3d, e).
Antiviral activity of GSNO in BALB/c mice
All the mice survived PCV2 inoculation with or without
GSNO treatment and none of the mice were clinically
affected during the study. There were no obvious gross
lesions in the tissues of the experimental animals.
GSNO treatment caused a significant increase in serum
NO levels in the mice during PCV2 infection (P < 0.05;
Fig. 4). As shown in Fig. 5a, the average daily weight gain
(ADWG) tended to decrease in the PCV2-inoculated con-
trol mice at 12–32 DPI, and was lower than that in the
NC mice (P > 0.05). However, the ADWG of the PCV2-
inoculated mice treated with GSNO was significantly
higher than that of PCV2-inoculated control mice (P <
0.05) at 22 and 32 DPI. An analysis of the kinetics of
spleen index (SI) and thymus index (TI) demonstrated
some GSNO-induced improvement in the mouse spleens
and thymuses during PCV2 infection from −1 to 32 DPI.
As shown in Fig. 5b and c, SI and TI were significantly
higher in the GSNO-treated mice at 12 DPI than that in
the untreated mice during PCV2 infection (P < 0.05 or
P < 0.01). SI of the PCV2-inoculated control mice also
decreased significantly at 12, 22 and 27 DPI compared
with that of the NC mice (P < 0.05 or P < 0.01) (Fig. 5b),
whereas TI decreased significantly in the PCV2-inoculated
control mice at 17 DPI (P < 0.05; Fig. 5c). However,
there were no significant differences in the SI and TI of
the GSNO-treated mice and NC mice at −1―32 DPI
(P > 0.05).
Throughout the experiment, all the serum samples ob-
tained from the NC mice were negative for PCV2-
specific nucleic acids when analyzed by gel-based PCR
and quantitative real-time PCR assays. In the PCV2-
inoculated mice, PCV2 DNA was detected by gel-based
PCR in the pooled tissue samples and serum samples,
and PCV2 DNA was determined in 75% (15/20) of the
tissue samples and in 70% (14/20) of the serum samples
from the PCV2-inoculated control mice between 12 and
32 DPI (Tables 1 and 2). However, the percentages of
PCV2-positive tissue samples and serum samples from
the GSNO-treated mice infected with PCV2decreased to
45% (9/20) and 40% (8/20) respectively (Tables 1 and 2).
Significant differences were also noted in the PCV2-
positive tissue samples (P = 0.012) and PCV2-positive
serum samples (P = 0.005) from the PCV2-inoculated
control mice and PCV2-inoculated mice treated with
GSNO (Tables 1 and 2). As described in Fig. 6, the num-
ber of PCV2 DNA copies reached a plateau at 12 DPI,
but declined to some extent between 12 and 32 DPI in
the PCV2-inoculated mice treated with or without GSNO.
Fig. 2 Kinetics of NO production in the culture supernatants of PK-15
cells. When 80% confluent monolayers formed, 125 μM GSNO or 125 μM
GSNO plus Hb (5, 10, 20 μM) were added into 96-well cell culture plates,
with four wells for each concentration, and untreated cells served as the
control. The supernatant from each sample was collected at different
time points, and the NO levels were determined by Griess reaction with
a microplate reader at 540 nm according to a standard curve made from
sodium nitrite. Data were presented as means ± SD from three
independent experiments. *P < 0.05, **P < 0.01 vs 125 μM
GSNO-treated group
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However, at 12–32 DPI, the number of PCV2 DNA copies
xwas significantly lower in the PCV2-inoculated mice
treated with GSNO at each time point compared with
those in the PCV2-inoculated control mice (P < 0.01;
Fig. 6).
Discussion
NO, an important cellular messenger, is involved in
complex and diverse functions in various physiological
and pathological processes, displaying a broad spectrum
of antimicrobial activities in vitro and in vivo [24]. In
this study, we verified the antiviral activity of the NO-
generating compound GSNO during PCV2 infection in
PK-15 cells and BALB/c mice.
The in vitro experiment showed that treatment with
GSNO induced significant declines in PCV2-infected
cells, viral titers and viral DNA copy numbers compared
with those of the PCV2-infected samples, whereas the
effect of GSNO was dose-dependently reversed by the
NO scavenger Hb. These results demonstrate that the
Fig. 3 Effects of GSNO on PCV2 replication in PK-15 cells. When monolayers reached about 80% in each well of 24-well cell culture plates, the
cells were incubated with 125 μM GSNO or 125 μM GSNO plus Hb (5, 10, 20 μM) for 6 h, with four wells for each treatment, then the cells were
infected with PCV2 (1 MOI) in the presence of various drugs for another 72 h. Non-treated cells served as the mock, and the infected cells without
drug treatment were considered as the PCV2-infected control. PCV2-positive cells were detected by IFA (a), and the appearance of infected cells
was judged by FITC staining intensity. The culture supernatant from each well was collected for determination of NO production (b), in addition,
the cells in each sample were also gathered for assay of the percentage of infected cells (c), virus titers (d), and viral DNA copies (e). Relative infected
cells (%) = number of PCV2-positive cells from experimental samples / number of PCV2-positive cells from PCV2-infected control × 100. Data
were presented as means ± SD from three independent experiments. *P < 0.05, **P < 0.01 vs PCV2-infected control
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NO donor GSNO exerts significant antiviral activity
against PCV2 replication in PK-15 cells. Similarly, in pre-
vious studies, the NO donor SNAP has been shown to
block the replication of severe acute respiratory syndrome
coronavirus (SARS coronavirus) [16], porcine parvovirus
[25] and porcine respiratory coronavirus [26]. Although
the inhibition of PCV2 by NO was clearly demonstrated
here, it is unclear whether the antiviral effect of the NO
donor GSNO was actually attributable to other factors. To
address this question, convincing evidence has been pre-
sented in this study. First, the data from a MTT assay
clearly excluded the possibility that antiviral effects of the
NO donor GSNO on PCV2 replication might have re-
sulted from its toxicity to the cells. Second, GSNO gener-
ated NO in the culture supernatant of PK-15 cells and NO
dose-dependently suppressed PCV2 replication. Finally,
the inhibitory effect of GSNO on PCV2 replication was
reversed by the NO scavenger, Hb. Overall, these results
strongly suggest that NO, generated from the donor
GSNO, inhibits the replication of PCV2 in PK-15 cells.
The mechanisms involved in the antiviral properties of
NO have partly been clarified in previous studies, which
have suggested that NO plays important roles in the
regulation of a viral protease [27], the innate immunity
of the host [15], and the synthesis of viral proteins and
nucleic acids [12]. Depending on its concentration, NO
exerts its antimicrobial effects in two ways: At low con-
centrations, NO acts as a signaling molecule that pro-
motes the growth and activity of immune cells, whereas
at high concentrations, NO covalently binds DNA, pro-
teins and lipids, thereby inhibiting or killing the target
Fig. 4 NO production in serum from the experimental mice. At 6
DPI, serum samples were obtained from six mice in each group for
NO detection by Griess reaction. Data were presented as means ± SD.
**P < 0.01 vs infected control
Fig. 5 Kinetics of ADWG, SI and TI from the experimental mice. Four samples were obtained from each group at the time of necropsy. a ADWG
(g/day) = (final weight – initial weight) / days; b SI =spleen weight (g) / the weight of mice (g) × 1000. c TI =thymus weight (g) / the weight of mice
(g) × 1000. Kinetics of ADWG, SI and TI demonstrated that, to some extent, GSNO improved growth performance and protected the immune organs
(spleens and thymuses) of the mice during PCV2 infection. Data were presented as means ± SD. *P< 0.05, **P< 0.01 vs PV2-inoculated control; #P< 0.05,
##P < 0.05 vs NC
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pathogen [28]. The antiviral activity of NO against
PCV2 was demonstrated in vitro by its reduction of the
numbers of virus-infected cells, viral titers and DNA
copy numbers. The decline in the number of virally in-
fected cells is probably attributable to the blockage of
viral penetration to the cytoplasm or to the suppression
of transcriptional steps mediated by NO [29], whereas
the reduced viral titers and viral DNA copy numbers are
probably attributable to the inhibition of viral protein
and nucleic acid synthesis by NO [12]. However, the
binding, cell entry and transcription characteristics of
PCV2 that are influenced by NO were not investigated
in this study. Therefore, the mechanisms underlying the
inhibition of PCV2 replication by NO remain to be eval-
uated in future studies.
Although the antiviral activity of GSNO was clearly
demonstrated in vitro, in vivo studies are also essential
to confirm the effects of GSNO on PCV2 infection under
clinical conditions. Mice, including BALB/c, C57BL/6,
C3H/HeJ and Kunming mice, are susceptible to PCV2,
although susceptibility to PCV2 is limited among the
above-mentioned mouse lines [30–32]. Therefore, the
mouse is important in the epidemiology of PCV2 and
can be used as an experimental model of PCV2. In this
study, BALB/c mice were artificially inoculated with
PCV2 and treated with or without GSNO. Our data
showed that GSNO treatment released a large amount
of NO, which contributed to the effective inhibition of
PCV2 replication in the mice. The poor growth perform-
ance and immune organ (spleen and thymus) dysfunction
induced by PCV2 infection were also improved to some
extent by GSNO. Previous reports have demonstrated that
dietary L-arginine supplementation induces significant in-
crease in serum NO production and suppresses PCV2
infection in mice [33, 34], suggesting that the antiviral ef-
fects of L-arginine are predominantly mediated by NO be-
cause L-arginine is the sole substrate for NO synthesis
[35]. This hypothesis was confirmed in our in vivo study,
because GSNO was the exogenous NO donor and re-
leased NO in mice. Although no weight loss or wasting
was observed in the PCV2-inoculated mice, as has been
described previously, the ADWG of the mice infected with
PCV2 decreased to some extent in the present study,
which might be be attributable to the different mouse line
used there. Since Kiupel et al. (2005) demonstrated that
PCV2 induces apoptosis by activating caspases 8 and 3 in
the spleens of infected mice [36]. Therefore, the impaired
immune organs detected in the PCV2-inoculated control
mice in our study might be attributable to the apoptosis
induced by PCV2. Interestingly, the GSNO treatment im-
proved growth performance and protected the immune
organs (spleen and thymus) of the PCV2-inoculated mice.
As we know, NO acts as a key molecule in inflammation
and the immune response [37, 38], so the NO-generating
compound GSNO may play a critical role in the regulation
of inflammation and immunity during PCV2 infection, as
well as inhibiting PCV2 replication, in mice. More re-
search is required to confirm this hypothesis.
Conclusions
GSNO, an exogenous NO donor, released NO into the
culture supernatants of PK-15 cells and the sera of
BALB/c mice. The antiviral effects of GSNO on PCV2
were also demonstrated in both PK-15 cells and BALB/c
mice. As well as the significant inhibition of PCV2, GSNO
also positively regulated the growth performance and im-
mune organs of the PCV2-infected mice. Therefore, NO
and its donor GSNO have potential valve as antiviral
Table 2 Incidence of PCV2 positive serum sample from the
experimental mice as detected by gel-based PCR analysis
Groups 12 DPI 17 DPI 22 DPI 27 DPI 32 DPI Total
NC 0/4 0/4 0/4 0/4 0/4 0/20
PCV2 3/4 3/4 3/4 2/4 3/4 14/20
PCV2 + GSNO 2/4 2/4 1/4 1/4 2/4 8/20
Data were presented as number of PCV2 PCR positive serum samples/number
of mice sampled
Fig. 6 PCV2 DNA copies, detected by Taqman real-time PCR, in the
sera samples from the mice with different treatments. Four sera samples
were collected from each group at the time of necropsy. Data were
presented as means ± SD. ** p< 0.01 vs PCV2-inoculated control
Table 1 Incidence of PCV2-positive tissue pool from the
experimental mice detected by gel-based PCR analysis
Groups 12 DPI 17 DPI 22 DPI 27 DPI 32 DPI Total
NC 0/4 0/4 0/4 0/4 0/4 0/20
PCV2 4/4 3/4 3/4 2/4 3/4 15/20
PCV2 + GSNO 2/4 2/4 2/4 1/4 2/4 9/20
The tissue pools consisted of liver, thymus, lung and spleen. Data were
presented as number of PCV2 PCR positive tissue pools/total number tissue
pools analyzed
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reagents during PCV2 infection. However, the mecha-
nisms underlying the antiviral activity of GSNO remain to
be investigated in our future studies. The effects of GSNO
on PCV2 infection in the target animal, the pig, must also
be evaluated.
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